Semaglutide is associated with a high prevalence of adverse events, and its long-term safety is unknown. In an observational ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

A game-changing medication known for diabetes and weight loss might also hold the key to improving liver health for millions of Americans.

Much has been learned about GLP-1s over many years, but little is understood about why the degree of response to them varies ...

Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...

However, many on Wall Street believe that better days lie ahead for Novo Nordisk. Analysts expect this obesity drug stock to ...

Adult patients taking Wegovy saw a reduced risk of experiencing a major adverse cardiovascular event within the first three months of treatment, according to a secondary analysis of the drug’s ...

Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...

New research reveals that semaglutide significantly improves liver health in MASH patients. A new study published in the New ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

When weight loss is equal, though, the GLP-1s seem to provide larger benefits. Researchers say prospective studies are needed ...

Limited effectiveness, weight regain, and high prevalence of adverse events are the three key limitations of ...